Asia Pacific Anti Diabetic Biosimilars Market By Drug Class (Insulin, Biguanides, Sulfonyl Ureas, Thiazolidinediones, Di Peptidyl Peptidase (DPP)-IV Inhibitors, ?-glucosidase Inhibitos, GLP-1 Agonists, SGLT-2 Inhibitors, Others), By Disease Type (Type-I Diabetes, Type-II Diabetes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Country

Purchase Option

$ 3100
$ 4600
$ 6900

Biosimilars are biological substances that are highly similar to biologics but not identical with patented biological molecules. These are manufactured after the patent expiration of original products. Anti-diabetic biosimilars are help to control the blood glucose levels in the diabetic patients. Commonly used anti-diabetic drugs include biguanides, sulfonyl ureas, GLP-1 receptor agonists, DPP-IV inhibitors, thiazolidinediones, and insulin among others. These are cost-effective molecules with similar potency and efficiency compared with reference biologic molecules.

Asia Pacific Anti diabetic Biosimilars Market report gives a comprehensive outlook across the regions with special emphasis on key countries such as Australia, China, India, Japan, Indonesia, Vietnam, South Korea, and Rest of APAC. The report gives historical, current, and future market sizes (US$ Mn) on the basis of drug class, disease type, distribution channel and countries. This report studies Asia Pacific Antidiabetic Biosimilars Market dynamics elaborately to identify the current market trends and drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the report includes competition analysis with a vividly illustrated competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the countries and market unmet needs (Product Opportunities). Key stakeholders of the report include suppliers, manufacturers, marketers, policymakers..

Asia Pacific Anti diabetic Biosimilars Market Dynamics

Increase in the prevalence of diabetes majorly in China and India, Patent expiries of block buster drugs and promising product pipeline and Rise in R&D activities for the innovation of Insulin biosimilars

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Asia Pacific Anti Diabetic Biosimilars Market Segmentation

By Drug Class
  • Insulin
  • Biguanides
  • Sulfonyl Ureas
  • Thiazolidinediones
  • Di Peptidyl Peptidase (DPP)-IV Inhibitors
  • ?-glucosidase Inhibitos
  • GLP-1 Agonists
  • Others
By Disease Type
  • Type-I Diabetes
  • Type-II Diabetes
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
By Country
  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Frequently Asked Questions

2022 is the base year and 2029 is the forecast year.

The report covers the asia pacific anti diabetic biosimilars market data: China, India, Japan, Australia & New Zealand

The asia pacific anti diabetic biosimilars market key players are Biocon, Merck Sharp & Dohme Corporation, Boehringer Ingelheim GmbH, Eli Lilly & Co. , Sanofi-aventis U.S. LLC

1.Executive Summary
2. Asia Pacific Anti Diabetic Biosimilars Market  Introduction 
2.1. Asia Pacific Anti Diabetic Biosimilars Market   - Taxonomy
2.2. Asia Pacific Anti Diabetic Biosimilars Market   - Definitions
2.2.1. By Drug Class
2.2.2. By Disease Type
2.2.3. By Distribution Channel
2.2.4. By Country
3. Asia Pacific Anti Diabetic Biosimilars Market  Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Asia Pacific Anti Diabetic Biosimilars Market  Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Asia Pacific Anti Diabetic Biosimilars Market   By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Insulin
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Biguanides
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Sulfonyl Ureas
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Thiazolidinediones
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Di Peptidyl Peptidase (DPP)-IV Inhibitors
5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. ?-glucosidase Inhibitos
5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
5.7. GLP-1 Agonists
5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.7.3. Market Opportunity Analysis 
5.8. Others
5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.8.3. Market Opportunity Analysis 
6. Asia Pacific Anti Diabetic Biosimilars Market  By Disease Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Type-I Diabetes
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Type-II Diabetes
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
7. Asia Pacific Anti Diabetic Biosimilars Market   By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Asia Pacific Anti Diabetic Biosimilars Market   By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. China
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. India
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Australia and New Zealand (ANZ)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Japan
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Rest of APAC
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.China Anti Diabetic Biosimilars Market  2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Insulin
9.1.2.Biguanides
9.1.3.Sulfonyl Ureas
9.1.4.Thiazolidinediones
9.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
9.1.6.?-glucosidase Inhibitos
9.1.7.GLP-1 Agonists
9.1.8.Others
9.2.  Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Type-I Diabetes
9.2.2.Type-II Diabetes
9.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
10.India Anti Diabetic Biosimilars Market 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Insulin
10.1.2.Biguanides
10.1.3.Sulfonyl Ureas
10.1.4.Thiazolidinediones
10.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
10.1.6.?-glucosidase Inhibitos
10.1.7.GLP-1 Agonists
10.1.8.Others
10.2.  Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Type-I Diabetes
10.2.2.Type-II Diabetes
10.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
11.Australia and New Zealand (ANZ) Anti Diabetic Biosimilars Market 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Insulin
11.1.2.Biguanides
11.1.3.Sulfonyl Ureas
11.1.4.Thiazolidinediones
11.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
11.1.6.?-glucosidase Inhibitos
11.1.7.GLP-1 Agonists
11.1.8.Others
11.2.  Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Type-I Diabetes
11.2.2.Type-II Diabetes
11.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
12.Japan Anti Diabetic Biosimilars Market 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Insulin
12.1.2.Biguanides
12.1.3.Sulfonyl Ureas
12.1.4.Thiazolidinediones
12.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
12.1.6.?-glucosidase Inhibitos
12.1.7.GLP-1 Agonists
12.1.8.Others
12.2.  Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Type-I Diabetes
12.2.2.Type-II Diabetes
12.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
13.Rest of APAC Anti Diabetic Biosimilars Market 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Insulin
13.1.2.Biguanides
13.1.3.Sulfonyl Ureas
13.1.4.Thiazolidinediones
13.1.5.Di Peptidyl Peptidase (DPP)-IV Inhibitors
13.1.6.?-glucosidase Inhibitos
13.1.7.GLP-1 Agonists
13.1.8.Others
13.2.  Disease Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Type-I Diabetes
13.2.2.Type-II Diabetes
13.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Biocon
14.2.2.Merck Sharp & Dohme Corporation
14.2.3.Boehringer Ingelheim GmbH
14.2.4.Eli Lilly & Co. 
14.2.5.Sanofi-aventis U.S. LLC
14.2.6.Samsung Bioepis
14.2.7.Mylan N.V. 
14.2.8.Wockhardt
15. Research Methodology 
16. Appendix and Abbreviations 
  • Biocon
  • Merck Sharp & Dohme Corporation
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co. 
  • Sanofi-aventis U.S. LLC
  • Samsung Bioepis
  • Mylan N.V. 
  • Wockhardt

Adjacent Markets